Abstract: Methods for improving the gastrointestinal tolerability of biguanide compounds and for treating metabolic disorders and/or inducing weight loss in patients in need thereof, particularly in individuals having a contraindication for treatment with biguanide compounds, are provided comprising administering delayed release formulations of such biguanide compounds, including metformin, targeted to the small intestine.

Abstract: A polymer composite composition wherein at least one of the constituents is a silicone ionomer and the other constituent is polymer.

Abstract: Sustained release pharmaceutical formulations comprising an antihyperglycemic drug or a pharmaceutically acceptable salt thereof are disclosed. The formulations provide therapeutic plasma levels of the antihyperglycemic drug to a human patient over a 24 hour period after administration.

Abstract: The invention relates to compositions and methods of treatment employing compositions comprising polyelectrolyte complexes. The compositions include a water-soluble first polyelectrolyte bearing a net cationic charge or capable of developing a net cationic charge and a water-soluble second polyelectrolyte bearing a net anionic charge or capable of developing a net anionic charge. The total polyelectrolyte concentration of the first solution is at least 110 millimolar. The composition is free of coacervates, precipitates, latex particles, synthetic block copolymers, silicone copolymers, cross-linked poly(acrylic) and cross-linked water-soluble polyelectrolyte. The composition may be a concentrate, to be diluted prior to use to treat a surface.

Abstract: Drugs are formulated as oral dosage forms for controlled release in which the release rate limiting portion is a shell surrounding the drug-containing core. The shell releases drug from the core by permitting diffusion of the drug from the core. The shell also motes gastric retention of the dosage form by swelling upon imbibition of gastric fluid to size that is retained in the stomach during the postprandial or fed mode.

Abstract: The present invention relates to the administration of compositions comprising an antiestrogen, preferably trans-clomiphene, for treating metabolic syndrome in a subject. The invention is also directed to methods for reducing fasting glucose levels in a subject by administering a composition comprising an antiestrogen, preferably trans-clomiphene.

Abstract: A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described.

Abstract: The present disclosure invention relates to medical devices treated with a solution comprising one or more solvents and a combination of chlorhexidine free base and a water-soluble chlorhexidine salt in a weight/weight ratio of between about 1:1 to about 1:5, preferably about 1:1.

Abstract: A malleable compound according to the invention for use as a disinfectant comprises water, 25 to 40% by weight of a solvent component comprising low-molecular, water-miscible alcohols, 1 to 10% by weight of an active bactericidal component, 3 to 6% by weight hydroxypropylated polygalactomannan with an etherification level of between 0.3 and 1.5 and 0.1 to 0.5% by weight boracic acid or an equivalent amount of boron ions.

Abstract: An antimicrobial composition with synergistic biocidal activity is described which comprises at least one antimicrobial polymeric biguanide and at least one antimicrobial vicinal diol, said vicinal diol comprises at least one monoalkyl glycol, monoalkyl glycerol, or monoacyl glycerol, to diminish or eliminate biofilm communities. Such synergistic interaction is effective in wound treatment, particularly for chronic wounds, burns and battlefield-induced wounds, as well as for disinfecting non-biological surfaces. The antimicrobial composition can also be prepared as viscous solutions or as gels. The antimicrobial composition may be added to a substrate and dried, such as to a catheter, or to a foam, or to a fiber wound dressing, or coated as a viscous solution or gel upon such devices, to provide controlled release antimicrobial activity.

Abstract: A method is provided for early treatment of steatosis, which method is based on early detection of steatosis based on the detection of CD36. CD36 is determined in a body fluid, and CD36 levels above a predetermined value is indicative of steatosis.

Abstract: The present invention relates to medically efficacious agents coated with substance that forms a liquid impermeable but gas permeable layer, the treatment of medical conditions therewith, and particularly medical conditions at least partially characterised by blockage or other malfunction of ducts of exocrine glands and especially ducts of sweat glands.

Abstract: The invention relates to a transparent, absorbent device for the dressing of wounds and insertion sites of percutaneous and drug delivery devices. The device provides 360 degree or complete circumferential protection of a wound or insertion site of a percutaneous or drug delivery device and comprises a hydrogel center and at least one absorbent material. The hydrogel center can optionally comprise a bioactive agent(s).

Abstract: The present disclosure provides therapeutic methods for prevention and treatment of type-2 diabetes comprising administering to the subject an effective amount of FTY720 or an analog.

Abstract: The present invention relates to compounds, intermediates used in the preparation of such compounds, processes for the preparation of such compounds of the formula VI and formula VII and such intermediates, pharmaceutical compositions comprising such compounds of the formula VI and such compounds of the formula VII, and the uses of such compounds of the formula VI and such compounds of the formula VII as antidiabetic, pre-antidiabetic, antiobesity and cardioprotective agents.

Abstract: The present invention relates to treatment of water, and more specifically to treatment of water using a stable formulation of polyhexamethylene biguanide (PHMB) and a liquid or solid zinc salt for the application and prevention algae in recirculated and stagnant water systems. The invention also encompasses methods of treating water that already contains PHMB.

Abstract: Methods of treating diseases diabetes are disclosed. Methods of modulating elevated fructosamine levels, elevated HbA1c levels, impaired glucose tolerance, and impaired fasting glucose are also disclosed. In some embodiments, methods include co-administration of a biguanide and a bile acid sequestrant. Drug products including a biguanide and bile acid sequestrants in combination are also disclosed.

Abstract: An in situ film-forming methyl acetate-based solution of at least one absorbable, segmented block copolymer with amorphous and semi-crystalline segments contains at least one bioactive agent which exhibits antimicrobial, anti-inflammatory, antiviral, anesthetic, hemostatic, and/or antineoplastic activity. The absorbable polymers can be a polyaxial copolyester, polyether-ester and polyether-ester urethane. The solution can be applied (e.g., sprayed or swabbed) onto animal and human skin or accessible body cavities to prevent or treat one or more disorders preventable or treatable by the bioactive agent therein.

Abstract: Provided herein are methods of treating or ameliorating hypercholemia or a cholestatic liver disease by administering to an individual in need thereof a therapeutically effective amount of an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising administering to an individual in need thereof a therapeutically effective amount of ASBTI or a pharmaceutically acceptable salt thereof.

Abstract: The invention relates to a composition that includes a first agent selected from the group consisting of an oxidative phosphorylation inhibitor, an ionophore, and an adenosine 5?-monophosphate-activated Protein kinase (AMPK) activator; a second agent that possesses anti-inflammatory activity; and a third agent that possesses serotonin activity.

Abstract: The invention relates to medicine, in particular to sanitary and hygiene, more specifically to methods for producing a disinfecting agent for decontaminating different types of water, including drinking water. The inventive disinfecting agent producing method by dissolving quaternary ammonium compounds in water in the presence of an active additive in the form of guanidines, consists in preparing an aqueous 1-15% guanidine solution by permanently agitating it at a temperature ranging from 30 to 90° C., in cooling the solution accompanied with a precipitation control, when the precipitation process is over, in filtering the solution by using a filter whose cell size ranges from 10 to 1 mkm and in adding the quaternary ammonium compounds into the solution in such away that the concentration thereof in said solution is equal to 0.1-3%.

Abstract: Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.

Abstract: The present invention relates to methods and compositions for the treatment of Myotonic Dystrophy type 1 (DM1) with an AMPK activator <eq.metformin or troglizazone>.

Abstract: Antimicrobial compositions are provided that include a hydroalcoholic solvent system comprising a lower C2-C5 alcohol and water; a cationic antimicrobial agent such as chlorhexidine gluconate; a fatty component containing at least one free hydroxyl group, such as a C12-C21 fatty alcohol, a C12-C21 fatty ester, a C12-C21 fatty ether, a C12-C21 fatty amide, and combinations thereof; and optionally an emollient ester such as diesters of bibasic acids and trimesters of citric acid. The compositions described herein display improved antimicrobial efficacy and improved cosmetic elegance. Methods of using the antimicrobial compositions are provided.

Abstract: The present invention is a dentinal drug delivery composition composed of cationic and/or neutral porous particles containing an effective amount of a therapeutic agent, a method for using the dentinal drug delivery to provide a dental treatment, and a method for identifying anti-inflammatory agents capable of diffusing through dentin.

Abstract: The invention relates to a process for reducing the residual amount of p-chloroaniline in chlorhexidine. Also, the invention relates to a process for preparing chlorhexidine, or a pharmaceutically acceptable salt thereof, which is free of potential genotoxicity. In addition, the invention refers to the said chlorhexidine, or a pharmaceutically acceptable salt thereof, which is free of potential genotoxicity. Further, the invention relates to an analytical HPLC method for the determination of potentially genotoxic impurities in samples of chlorhexidine, or of a pharmaceutically acceptable salt thereof. The invention also relates to stabilized chlorhexidine digluconate salt free of potential genotoxicity in aqueous solution, and to a method for stabilizing chlorhexidine digluconate salt free of potential genotoxicity in aqueous solution.

Abstract: The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and/or a SGLT-2 inhibitor drug, and metformin XR, processes for the preparation thereof, and their use to treat certain diseases.

Abstract: The invention relates to a compound of formula (I), wherein the radicals R1 to R2 have the meaning according to claim 1, and/or physiologically acceptable salts thereof for the use for the prevention and/or treatment of cancer.

Abstract: Use of a composition for treating Alzheimer's disease, osteoporosis, sleep apnea, erectile dysfunction, McArdle disease, or a carbohydrate metabolism disorder, or for reducing aging or fatigue. The composition includes a first agent selected from the group consisting of an oxidative phosphorylation inhibitor, an ionophore, and an adenosine 5?-monophosphate-activated protein kinase activator; a second agent that possesses anti-inflammatory activity; and a third agent that possesses serotonin activity.

Abstract: The present invention provides composites comprising at least one bioactive agent entrapped within a matrix of at least one metal; wherein said composite controllably releases at least one of said bioactive agent and metal or ion thereof, processes for the preparation of composites of the invention, compositions and products comprising composites of the invention and various uses thereof.

Abstract: A method for treating a surface with a therapeutic agent is disclosed. The method comprises precipitating a therapeutic agent from a hydrophilic polymeric base layer with which the therapeutic agent has been complexed, to form a layer comprising microparticles of the therapeutic agent on the hydrophilic polymeric base layer, the hydrophilic polymeric base layer being grafted to the surface. Devices comprising a surface having a hydrophilic polymeric base layer comprising a hydrophilic polymer grafted to the surface and a layer comprising microparticles of a therapeutic agent disposed on and complexed with the hydrophilic polymeric base layer are also disclosed.

Abstract: The present invention provides an immediate release pharmaceutical formulation which includes a tablet or capsule formulation comprising metformin and the sodium dependent glucose transporter (SGLT2) inhibitor dapagliflozin or its propylene glycol hydrate. The present invention also provides methods of preparing the formulations and methods of treating diseases or disorders associated with SGLT2 activity employing these formulations.

Abstract: Provided herein are methods and compositions comprising bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents and/or FXR agonists for the treatment of pancreatitis or prevention of pancreatitis.

Abstract: A method for blocking, neutralizing, or killing microorganisms that cause infectious disease in a mammal prior to or during the mammal encountering a contaminated environment or item includes: identifying a contaminated environment or item, wherein the contaminated environment or item is known or expected to be contaminated with harmful viral, fungal, or bacterial microorganisms; and administering a therapeutically effective amount of a barrier-forming composition to a mucosa of the mammal prior to or during the mammal encountering the contaminated environment or item. The barrier-forming composition provides a barrier on the mucosa that inhibits the microorganisms from contacting the mucosa. Other related methods are also included.

Abstract: The present invention relates to a composition containing at least one polyphenol, at least one polyethylene glycol and/or a functional equivalent and at least one glycol ether and/or a functional equivalent for application as a medicinal product. The composition according to the invention can also be used as a food supplement or nutraceutical.

Abstract: This invention relates to a “high lower alcohol content” (>40% v/v of a C1-4 alcohol) liquid composition able to be dispensed as a stable foam with the use of non-propellant foam dispensing devices from non-pressurized containers. The liquid compositions comprise an alcohol, C1-4 (>40% v/v), a silicone-based surfactant of at least 0.001% by weight to prepare a foamable composition, 0-10% w/w of additional minor components added to obtain the desired performance (a foamable composition), and the balance being purified water. The compositions may include emulsifier-emollients and moisturizers, secondary surfactants, foam stabilizers, fragrances, antimicrobial agents, other type of medicinal ingredients, and the like ingredients or additives or combinations thereof commonly added to alcohol gels or foams, aerosol compositions or to toiletries, cosmetics, pharmaceuticals and the like.

Abstract: Compositions and methods for treating and preventing cancer, particularly lung cancer, lymphangioleiomyomatosis and asthma are provided.

Abstract: A main object of the present invention is to provide a novel coated tablet which contains a drug having a guanidino group and does not suffer an obvious color change even when packed in a one-dose pack together with a drug having a (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl (DMDO) group. The present invention provides a coated tablet characterized in that an uncoated tablet containing a drug having a guanidino group has been coated with a polyvinyl alcohol for film coating which comprises polyvinyl alcohol, acrylic acid, and methyl methacrylate.

Abstract: Compositions, solid polymeric compositions, and/or articles of manufacture are provided that can include a polymer matrix having a plurality of ion-exchange particles distributed therein. Products by process are provided that can include prior to solidifying the polymeric precursors, blending the precursors with ion-exchange particles to form a mixture, and solidifying the mixture to form a solid polymeric composition product. Solid polymeric composition production methods are also provided that can include providing a plurality of ion-exchange particles, prior to solidifying the polymeric precursors, blending the precursors with the ion-exchange particles to form a mixture, and solidifying the mixture to form a solid polymeric composition. Article of manufacture production methods are provided that can include incorporating a solid polymeric composition into an article of manufacture, the solid polymeric composition including a polymer matrix and a plurality of ion-exchange particles distributed therein.

Abstract: This invention relates to ophthalmic disinfecting and preserving compositions. More particularly, this invention relates to multi-purpose disinfecting solutions [MPDS] suitable for use in or with storage cases for treating multiple-use contact lenses and/or for preserving, disinfecting or packaging of contact and other ophthalmic lenses.

Abstract: Antimicrobial silicone-based dressings, such as wound dressings, are disclosed. An example dressing comprises a transparent and self-adhesive gel sheet cured from a liquid containing silicone, the sheet having dispersed therein (i) particulates of a chlorhexidine compound that is not soluble in the liquid; and (ii) at least one other antimicrobial. Methods of making the silicone-based dressings and methods of use are also disclosed.

Abstract: The present invention is a dentinal drug delivery composition composed of cationic and/or neutral porous particles containing an effective amount of a therapeutic agent and a method for using the same to provide a dental treatment.

Abstract: The present invention relates to the use of compounds of general formula (I): (I) for the preparation of medicaments that act against mitochondrial pathologies involving a deficiency in ATP production via the oxidative phosphorylation pathway, such as mitochondrial diseases.

Abstract: The present invention relates generally to particles that include one or more antimicrobial agents therein and/or thereon. The particles may be provided with one or more coatings that contain one or more antimicrobial agents, or the one or more antimicrobial agents may be embedded in the particles. The present invention also relates to goods such as medical devices, personal care products, and household devices that incorporate one or more antimicrobial particles. The goods may be provided with one or more coatings that contain the antimicrobial particles, or the antimicrobial particles may be physically embedded in the medical devices. The present invention is further directed towards methods of making such medical devices. The goods incorporating the antimicrobial particles may be used in accordance with methods of killing microorganisms and preventing infections.

Abstract: The invention provides compositions and methods for determining insulin resistance and/or pancreatic ?-cell dysfunction in a subject. The invention also provides compositions and methods for treating a subject according to the insulin resistance and/or pancreatic ?-cell dysfunction in the subject.

Abstract: A biguanide derivative compound with N4-N5 substitution, which is represented by Formula 1, or a pharmaceutically acceptable salt thereof, a method of preparing the same, and a pharmaceutical composition containing the same as an active ingredient are provided. The biguanide derivative may exhibit excellent effect on activation of AMPK and inhibition of cancer cell proliferation in a low dose, compared with conventional drugs, and thus, may be useful to treat diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, cancer, etc.

Abstract: A biocide composition, comprising 2-methylisothiazolin-3-one as a biocidal active ingredient and at least one further biocidal active ingredient, as an additive to materials capable of being attacked by harmful microorganisms, wherein the composition comprises a pyrithione as the further biocidal active ingredient.

Abstract: The invention relates to a sterile wound dressing having a backing and a nonabsorbent elastomer wound contact layer, wherein the elastomer matrix is formed by a synthetic three-block elastomer, preferably a copolymer of polystyrene block and polyolefin block (SEPS, SEBS, SEEPS, etc.) or mixtures thereof, wherein the total polymer content is less than 3.2 wt %, in particular 3.0 wt % or less, preferably 2.6 wt % or less, and is plasticized by an apolar oil and/or petroleum jelly.

Abstract: The present invention relates to metformin extended release (XR) formulations with improved compactability to provide reduced mass tablets, granulations, and capsules.

Abstract: The present invention discloses liquid precursor compositions adapted for application on a hard surface in the oral cavity, comprising at least one therapeutic agent suitable for the treatment of oral disorders, at least one acidic-pH sensitive polymer, at least one hydrophobic polymer, and a pharmaceutically acceptable volatile carrier, wherein a weight ratio between said at least one hydrophobic polymer and said at least one acidic-pH sensitive polymer is larger than 1. The invention also discloses formulations formed of the solidification of these compositions, and methods for treating oral disorders by applying these compositions on hard surfaces in the oral cavity or to be placed in the oral cavity.